Holen Sie sich die Stockscreener-App
2.17
11.86%
0.23
Schlusskurs vom Vortag:
$1.94
Offen:
$1.98
24-Stunden-Volumen:
43,768
Relative Volume:
0.19
Marktkapitalisierung:
$73.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-41.36M
KGV:
-1.3232
EPS:
-1.64
Netto-Cashflow:
$-42.09M
1W Leistung:
+13.61%
1M Leistung:
+12.44%
6M Leistung:
+10.15%
1J Leistung:
-14.23%
1-Tages-Spanne:
$1.94
$2.24
1-Wochen-Bereich:
$1.85
$2.24
52-Wochen-Spanne:
$0.8981
$3.4154
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Firmenname
Armata Pharmaceuticals Inc
Sektor
Branche
Telefon
310-655-2928
Adresse
4503 Glencoe Avenue, Marina del Rey, CA
Vergleichen Sie ARMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
2.17 | 73.83M | 0 | -41.36M | -42.09M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-06-19 | Eingeleitet | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Aktie (ARMP) Neueste Nachrichten
Armata Pharmaceuticals Elects Board Members at Annual Meeting - TipRanks
Chronic Pseudomonas aeruginosa Pulmonary Infections Pipeline - openPR.com
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Seeking Alpha
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0% - Defense World
10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io
ARMP Soars 72% in a Month Following Infectious Disease Study Success - MSN
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Biotech Alert: Searches spiking for these stocks today - TipRanks
Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Inter - GuruFocus
Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $9.00 at HC Wainwright - Defense World
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | ARMP Stock News - GuruFocus
Armata Pharmaceuticals (ARMP) Receives Boosted Price Target from - GuruFocus
HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating - marketscreener.com
Armata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Tria - GuruFocus
Armata reports data from Phase 1b/2a diSArm trial - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Trial | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates - MSN
Armata Pharmaceuticals Inc (ARMP) Q1 Earnings: EPS Loss of $0.18 - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - Financial Times
New Strong Sell Stocks for May 8th - The Globe and Mail
Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World
Armata Pharmaceuticals secures additional DoD funding - Investing.com
Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 | ARMP Stock News - GuruFocus
Armata Pharmaceuticals secures additional DoD funding By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
New Strong Sell Stocks for April 28th - The Globe and Mail
New Strong Sell Stocks for April 24th - TradingView
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World
Bacteriophage Therapy Market Future Business Opportunities - openPR
HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World
Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN
Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire
Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter
Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia
Armata Pharmaceuticals secures $10 million credit - Investing.com India
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress
Finanzdaten der Armata Pharmaceuticals Inc-Aktie (ARMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):